Summary of findings 5. RISPERIDONE versus ZIPRASIDONE ‒ long‐term data (> 12 months) for people with severe mental illness and co‐occurring substance misuse.

RISPERIDONE versus ZIPRASIDONE‐ all data long term data (>12 months) for people with severe mental illness and co‐occurring substance misuse
Patient or population: people with severe mental illness and co‐occurring substance misuse Setting: Outpatients, United States Intervention: RISPERIDONE Comparison: ZIPRASIDONE
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	№ of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with ZIPRASIDONE	Risk with RISPERIDONE
Leaving the study early: any reason	Study population		RR 0.96 (0.85 to 1.10)	240 (1 RCT)	⊕⊕⊝⊝ low1 2
	819 per 1000	787 per 1000 (696 to 901)
	Moderate
	819 per 1000	787 per 1000 (696 to 901)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

¹ Risk of attrition bias high but this does not affect this outcome

² Optimal information size criterion met but estimate includes both appreciable harm and benefit. Total sample size small